ABRACL and hepatocellular carcinoma: In contrast, a substantial proportion of the 263 signature genes linked to the more aggressive HCC subtype (S-III, poor prognosis) exhibited increased RPS either after birth (46 genes; typically, FGL2 and POSTN, both involved in leukocyte activation) or during early development (25 genes; remarkably, the cell proliferation marker, ABRACL) (Fig. 4b–d; Supplementary Fig. S10d, e, Table S1 and Data S1).